EMA Recommends Granting a Marketing Authorisation for Aumolertinib By Ogkologos - January 8, 2026 498 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of patients with EGFR-mutated NSCLC Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Temporary Interruption of Adjuvant Endocrine Treatment to Attempt Pregnancy Does Not... May 8, 2023 Workout Wednesday – Upper Body Stretches July 1, 2020 Survivorship and Immune Checkpoint Inhibitors July 21, 2020 EMA Recommends Extension of Therapeutic Indications for Trifluridine/Tipiracil July 7, 2023 Load more HOT NEWS FDA Grants Accelerated Approval to Tovorafenib for Patients with Relapsed or... First-Line Pembrolizumab Continues to Show Durable Clinical Benefit After 5 Years... EMA Recommends Granting a Marketing Authorisation for Generic Trabectedin Zenocutuzumab Approved to Treat Lung and Pancreatic Cancers with Rare Genetic...
